Electra Therapeutics
PrivateLast Round
Series C
Oct 22, 2025
Est. Valuation
$479M
Total Funding Raised
$267M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Electra Therapeutics is a biotechnology company developing antibody therapies that target signal regulatory proteins to treat immunological diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Electra Therapeutics Comparables
Compare Electra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ALX Oncology | 84% | |
| Biosion, Inc. | 81% | |
| Alector | 78% |
Electra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 22, 2025 | ||||
| Series B | Feb 16, 2022 |
Electra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| RA Capital Management | Series C, Series B |
| New Leaf Venture Partners | Series C, Series B |
| EQT Life Sciences | Series C |
| Westlake Village BioPartners | Series C, Series B |
| Cowen Private Investments | Series B |
| Cormorant Asset Management | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 20% QoQ, from 40 to 48 employees.
- Jul 25, 2026
Monthly visitors grew 92% MoM, reaching 3.8K.
Recent news
Latest coverage and updates
- receives_financingSep 18, 2026
Electra Therapeutics Inc. received financing of $350M in IPO on Sep 18th '26.
- is_developingSep 10, 2026
Electra Therapeutics Inc. is developing ELA822 on Sep 10th '26.
- hiresSep 9, 2026
Electra Therapeutics Inc. hired Clark as Vice President, Strategy and Finance on Dec 1st '25.
- promotesSep 9, 2026
Electra Therapeutics Inc. promoted Chris Clark to Chief Financial Officer on Sep 9th '26.
- goes_publicAug 28, 2026
Electra Therapeutics Inc. was planning to go public on Aug 28th '26.
Electra Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Electra Therapeutics's valuation, stock price, and market status.
Is Electra Therapeutics a public or private company?
Electra Therapeutics is a private company.
What is the current stock price of Electra Therapeutics?
Electra Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Electra Therapeutics worth (valuation)?
Valuation information for Electra Therapeutics is not publicly available.
Can I buy Electra Therapeutics stock?
Electra Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Electra Therapeutics's last funding round?
Electra Therapeutics's most recent funding round was Series C on October 22, 2025.
Who are the main investors in Electra Therapeutics?
Key investors in Electra Therapeutics include EQT Life Sciences, Westlake Village Biopartners, OrbiMed, Nextech Invest, Star Therapeutics.
Will Electra Therapeutics IPO soon?
No public IPO plans have been announced for Electra Therapeutics.
How can I track Electra Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Electra Therapeutics's secondary market activity and sign up for updates.